Báo cáo khoa học: Tumor suppressor p16INK4a: Downregulation of galectin-3, an endogenous competitor of the pro-anoikis effector galectin-1, in a pancreatic carcinoma model

Tumor suppressor p16INK4a: Downregulation of galectin-3, an endogenous competitor of the pro-anoikis effector galectin-1, in a pancreatic carcinoma model Hugo Sanchez-Ruderisch1,*, Christian Fischer1, Katharina M. Detjen1, Martina Welzel1, Anja Wimmel1, Joachim C. Manning2, Sabine Andre´ 2 and Hans-Joachim Gabius2

1 Medizinische Klinik m.S. Hepatologie und Gastroenterologie, Charite´ -Universita¨tsmedizin Berlin, Germany 2 Institut fu¨ r Physiologische Chemie, Ludwig-Maximilians-Universita¨ t Mu¨ nchen, Germany

Keywords anoikis; galectin; glycosylation; integrin; pancreatic carcinoma

Correspondence K. M. Detjen, Charite´ -Universita¨ tsmedizin Berlin, Campus Virchow-Klinikum, Med. Klinik m.S. Hepatologie und Gastroenterologie, Augustenburger Platz 1, D-13353 Berlin, Germany Fax: +49 30 450 559939 Tel: +49 30 450 559679 E-mail: katharina.detjen@charite.de

*Present address Center for Cardiovascular Research, Charite´ - Universita¨ tsmedizin Berlin, Germany

(Received 20 May 2010, revised 1 July 2010, accepted 5 July 2010)

The tumor suppressor p16INK4a has functions beyond cell-cycle control via cyclin-dependent kinases. A coordinated remodeling of N- and O-glycosyla- tion, and an increase in the presentation of the endogenous lectin galectin- 1 sensing these changes on the surface of p16INK4a-expressing pancreatic carcinoma cells (Capan-1), lead to potent pro-anoikis signals. We show that the p16INK4a-dependent impact on growth-regulatory lectins is not lim- ited to galectin-1, but also concerns galectin-3. By monitoring its expression in relation to p16INK4a status, as well as running anoikis assays with galec- tin-3 and cell transfectants with up- or downregulated lectin expression, a negative correlation between anoikis and the presence of this lectin was established. Nuclear run-off and northern blotting experiments revealed an effect of the presence of p16INK4a on steady-state levels of galectin-3-spe- ciﬁc mRNA that differed from decreasing the transcriptional rate. On the cell surface, galectin-3 interferes with galectin-1, which initiates signaling toward its pro-anoikis activity via caspase-8 activation. The detected oppo- site effects of p16INK4a at the levels of growth-regulatory galectins-1 and -3 shift the status markedly towards the galectin-1-dependent pro-anoikis activity. A previously undescribed orchestrated ﬁne-tuning of this effector system by a tumor suppressor is discovered.

doi:10.1111/j.1742-4658.2010.07764.x

Introduction

In detail,

enhanced production of

The tumor suppressor p16INK4a, a frequent target for deletion mutations underlying carcinogenesis, is known as a binding partner of cyclin-dependent kinases CDK4 and CDK6, interfering with their association with D-type cyclins [1,2]. Emerging evidence broadens the spectrum of p16INK4a functionality beyond cell- cycle control. In fact, recent experiments have unrav- eled an effect on distinct aspects of gene expression. One functional consequence is to restore the suscepti- bility of tumor cells to anoikis (the category of apopto- sis caused by inadequate or inappropriate cell–matrix

contacts). the a5-integrin subunit and also an increased cell-surface presence of a5b1-integrin (the ﬁbronectin receptor) were detected in p16INK4a-restituted Capan-1 pancre- atic carcinoma cells [3]. Routing of this glycoprotein and the levels of its cell-surface presentation, binding activity and capacity for downstream signaling may, in principle, depend not only on the protein part, but also on its glycosylation. Because the ﬁbronectin recep- tor is heavily glycosylated with 26 sites for N-glycosyl- ation [4] and variations in the structures of glycan

Abbreviations Gal-1, galectin-1; Gal-3, galectin-3; PCNA, proliferating cell nuclear antigen; poly-HEMA, poly(2-hydroxyethyl methacrylate).

FEBS Journal 277 (2010) 3552–3563 ª 2010 The Authors Journal compilation ª 2010 FEBS

3552

H. Sanchez-Ruderisch et al.

p16INK4a downregulates anti-anoikis effector Gal-3

chains, such as status of sialylation, have a bearing on protein functions in general and on integrins in partic- ular [5–8], glycan remodeling affords an attractive level of regulation of integrin functionality. The assumption of a modulatory impact of p16INK4a at the level of gly- cosylation was a reasonable and testable hypothesis. This hypothesis was veriﬁed by combining glycogene microarray analysis, chromatographic glycan proﬁling and lectin binding [9]. Inﬂuencing N- and O-glycan galactosylation and sialylation, salient biochemical sig- nals in protein–carbohydrate ⁄ protein interplay [10–12], have thus become a new aspect of p16INK4a functional- ity. Hereby, the tumor suppressor can affect integrin processing and routing, as well as its afﬁnity for protein ligands.

and phosphoinositide 3-kinase activities, as well as a signal attenuating extracellular signal-regulated kinase [23]. This is in accordance with the lack of aberrantly enhanced extracellular signal-regulated kinase signaling in pancreatic tumors which harbor the mentioned gene defect [24]. Third, Gal-3 protects BT549 breast cancer cells from anoikis [25]. Fourth, Capan-1 wild-type cells are known to express Gal-3 [26]. On this basis, we investigated the inﬂuence of the presence of p16INK4a on the level of Gal-3 production and possible func- tional competition between galectins-1 and -3. The reported results document the relevance of Gal-3 in interfering with anoikis induction and, more impor- tantly, shed light on the intriguing capacity of this tumor suppressor to coordinately exploit this aspect of the galectin network.

lectins, which translate

Results

Expression of p16INK4a decreases the level of Gal-3

In addition, modiﬁed glycan chains can be engaged the cell surface with in recognitive interactions at endogenous sugar-encoded messages into cellular responses [13–15]. Even seem- ingly small modiﬁcations can act as potent switches of afﬁnity. In fact, altering branch-end positions, the sta- tus of core substitutions and glycan density strongly affects lectin reactivity, as measured for example for members of the family of adhesion ⁄ growth-regulatory galectins [16–19]. Fittingly for a functional implication, microarray analysis on a set of 1996 cancer-associated genes, proteomic proﬁling and cytoﬂuorometry and anoikis assays revealed the upregulation of homo- dimeric galectin-1 (Gal-1) as a carbohydrate-binding effector for anoikis induction under the control of p16INK4a [9]. Thus, this tumor suppressor sensitizes cells for the onset of anoikis by increasing the comple- mentary sides of pro-anoikis protein–carbohydrate interactions.

for Gal-3 was

signals

immunohistochemically. The

As the term Gal-1 implies, the functionality of this protein might be embedded in a network with other family members [20]. This raises the possibility of addi- tive or antagonistic effects. Exploring this issue, model studies on SK-N-MC neuroblastoma cells illustrated the potential of other galectins, especially galectin-3 (Gal-3), to factor in growth inhibition by Gal-1 at the level of cell-surface ligand binding [21,22]. Having connection between recently delineated a direct p16INK4a and Gal-1 [9], the question arises as to whether the inﬂuence of p16INK4a is restricted to this family member. The following four lines of evidence direct the focus of attention on Gal-3. First, it is func- tionally antagonistic to Gal-1 in the neuroblastoma system by blocking access to ganglioside GM1, the common galectin ligand on the cell surface in these cells [21]. Second, activating K-ras mutations are com- mon in pancreatic cancer, and Gal-3 (but not Gal-1) interacts with oncogenic K-ras–GTP to promote Raf-1

In order to delineate any impact of the tumor suppres- sor p16INK4a on Gal-3 expression we worked with Capan-1 pancreatic carcinoma wild-type and vector- transfected cells (mock) as well as three independently generated clones stably transfected with p16INK4a tumor suppressor cDNA (p16 1-3). Of note, these clones had been studied previously, revealing increased expression and cell-surface presentation of the a5-integrin subunit and Gal-1 [3,9]. Western blot analyses ﬁrst resulted in the expected pattern for the p16INK4a protein, then con- ﬁrmed the reported presence of Gal-3 in Capan-1 wild- type cells [26] and excluded an effect of the control transfection on Gal-3 and general protein synthesis (Fig. 1A). In contrast to the mock process, the presence of p16INK4a protein had an effect. A clear decrease in invariably the intensity of observed, although proliferating cell nuclear antigen (PCNA) staining as a control for loading remained rather constant (Fig. 1A,B). To examine whether such a negative correlation between Gal-3 and p16INK4a can also be seen in vivo, we processed routinely ﬁxed sec- tions from normal pancreas tissue and pancreatic can- cer resulting staining proﬁles, shown in Fig. S1, conﬁrmed an inverse expres- sion pattern in accordance with the in vitro data. In principle, Gal-3 can act as an anti-anoikis effector in the cell and ⁄ or at the cell surface, for example, blocking Gal-1 functionally as seen previously in a neuroblas- [21]. In view of the proven pro-anoikis toma model cell-surface activity of Gal-1, the cultured cells provided the hypothesis of reduced the opportunity to test

FEBS Journal 277 (2010) 3552–3563 ª 2010 The Authors Journal compilation ª 2010 FEBS

3553

H. Sanchez-Ruderisch et al.

p16INK4a downregulates anti-anoikis effector Gal-3

A

B

cell-surface expression of Gal-3. Indeed, cytoﬂuorimet- ric monitoring of mock-transfected and p16INK4a-resti- tuted Capan-1 cells revealed that cell-surface Gal-3 was downregulated (Fig. 1C). As reported previously [9], Gal-1 cell-surface presentation determined in the con- trol increased (not shown). The presence of the tumor suppressor thus reduced the level of Gal-3 and its cell- surface presentation. To further test whether Gal-3 pro- tein abundance was regulated by prolonged culture in suspension, we maintained cells for up to 24 h under this condition, with the percentage of cells undergoing anoikis increasing as expected in p16INK4a-expresssing cells (Fig. 2A). Loss of anchorage did not notably change the level of Gal-3 detected in western blots (Fig. 2B). These results document a signiﬁcant decrease in the presence of Gal-3 in tumor-suppressor-positive cells, which is not further enhanced in suspension cul- ture. This suggests regulation at the level of transcrip- tion, as previously detected for Gal-1 [9]. To test this, we determined the steady-state mRNA concentration by northern blotting and the de novo transcription rate by run-off assays.

p16INK4a negatively affects Gal-3 mRNA availability

C

0 0 1

100

101

102

103

104

101

102

103

104

100

signal

intensities

in samples

Northern blotting using samples from p16INK4a-positive cells revealed a conspicuous decrease in the availability of Gal-3-speciﬁc mRNA, when compared with mock- transfected controls, whereas similar mRNA levels for the housekeeping gene GAPDH were present irrespec- tive of cell status (Fig. 2C, left). This diminished steady- state amount may be because of alterations in de novo run-off assays, production or availability. Nuclear which report on de novo synthesis, revealed rather simi- lar from mock- and p16INK4a-transfected cells for the two tested housekeep- ing genes and for Gal-3 (Fig. 2C, right). De novo Gal-1 gene transcription, by contrast, increased signiﬁcantly in the presence of the tumor suppressor (not shown). Thus, the transcriptional rate is a major factor in increasing the production of Gal-1, whereas post-transcriptional processes decrease Gal-3 production. We propose a functional relevance for this alteration. In order to prove an effect of Gal-3 on anoikis in this cell system, especially regarding a functional antagonism with Gal-1 at the level of the cell surface, we followed three routes of investigation to test the validity of this assumption.

Gal-3 is an inhibitor of anoikis

Fig. 1. p16INK4a restitution inhibits Gal-3 expression. (A) Western blot after 1D SDS ⁄ PAGE [15% gel, proteins blotted onto poly(vinyli- dene ﬂuoride)] with protein extracts from Capan-1 wild-type (wt), mock-transfected and three p16INK4a-expressing clones incubated with antibodies to p16INK4a, Gal-3 and PCNA, respectively. The level of Gal-3 is reduced in p16INK4a-expressing clones. (B) Western blot after 2D gel electrophoresis with protein extract from mock-trans- fected (1,2: 200, 400 lg) and p16INK4a-transfected cells (3,4: 200, 400 lg). Residual protein in gels was visualized by silver staining (lower part of each panel) and each blotting procedure included a positive control with Gal-3 (top right). (C) Quantitation of cell-sur- face presentation of Gal-3 in mock-transfected (left) and p16INK4a- expressing Capan-1 pancreatic cancer cells (right). The control for antigen-independent staining by omitting the incubation step with the lectin-speciﬁc antibody from the protocol is given in each panel (gray area), as are the percentage of positive cells and the mean ﬂuorescence intensity of staining when incubating with 20 lgÆmL)1 non-cross-reactive anti-galectin-3 Ig. Standard deviation did not exceed 11% in experimental series with four different experiments run in triplicates.

In the ﬁrst set of experiments, we tested the capacity of Gal-3 to block anoikis in p16INK4a-expressing cells

FEBS Journal 277 (2010) 3552–3563 ª 2010 The Authors Journal compilation ª 2010 FEBS

3554

H. Sanchez-Ruderisch et al.

p16INK4a downregulates anti-anoikis effector Gal-3

A

0 2 1

0 0 2

0 9

0 5 1 0 2 1 0 9

0 6

0 5 1 0 0 1

Mock

0 6

0 3

0 5

0 3

200

400

600

200

400

600

200

400

600

200

400

FL2-H

s t n u o 0C

0 8

0 6

0 6 1 0 2 1

0 8

0 4

0 2 0 6 1 0 2 1 0 8

p16-3

0 4

0 2

0 4

0 6 0 5 0 4 0 3 0 2 0 1

200

600

200

600

200

400

600

400 FL2-H

FL2-H

400 FL2-H

16

24 Time (h)

0

8 B

C

Fig. 2. The level of Gal-3 is diminished in p16INK4a-expressing clones but remains constant over the 24 h anoikis induction period. (A) Repre- sentative FACS histograms illustrating the increased extent of anoikis induction in Capan-1 ⁄ p16INK4a-positive cells compared with a mock- transfected clone. Cells were harvested following incubation on poly-HEMA to preclude attachment and trigger anoikis for the indicated time. The given numbers indicate the percentage of cells with subdiploid DNA content (pre-G1 fraction). (B) Western blot analysis from extracts obtained under the conditions described above and analyzed with anti-Gal-3 or anti-PCNA Ig as indicated. (C) Poly-(A+) RNAs were isolated from mock-transfected and p16INK4a-expressing clones and northern blots were probed for the presence of mRNA speciﬁc for Gal-3 or GAPDH (left). In vitro elongation of de novo RNA transcripts was performed in isolated nuclei from mock-transfected and p16INK4a- expressing clones in the presence of [32P]UTP[aP], and the radioactively labeled RNA was hybridized to immobilized cDNA for Gal-3, GAPDH and b-actin (right). One representative of three experiments that yielded similar results is shown.

the availability of

clones revealed a trend towards reduced anoikis sus- ceptibility. This reached statistical signiﬁcance in clone Gal-3 ⁄ 2 (Fig. 4B). Results showing that exogenous addition and vector-directed overexpression of Gal-3 can reduce the level of anoikis shaped the notion that Gal-3 physically hampers the induction of this cell death program. In this case, even p16INK4a-negative cells should become sensitized toward anoikis if their Gal-3 production is downregulated. This reasoning led to the third set of experiments.

when added to the medium. As shown in Fig. 3, expo- sure of cells to Gal-3 was inhibitory in this experimen- tal setting. The percentage of p16INK4a-positive cells undergoing anoikis after 20 h in suspension was reduced when kept in the presence of suitable concen- trations of Gal-3. To further strengthen the link this between Gal-3 and anoikis, lectin was upregulated deliberately by generating p16INK4-positive cells, which additionally express Gal-3 at a high level via a second transfection. Thus, the presence of Gal-3 was increased, counteracting the p16INK4a-dependent downregulation. A series of ﬁve clones was obtained with notably enhanced Gal-3 con- centration, an unspeciﬁc inﬂuence of the second trans- fection step rendered unlikely by a mock control (Fig. 4A). The level of anoikis in these control cells was used as a reference, and four Gal-3-overexpressing

To test the given hypothesis, we generated clones harboring an antisense vector for Gal-3. Because of this engineering, the clones contained a lower level of Gal-3 than wild-type and mock-transfected cell popula- tions (Fig. 4C). Measurements of the corresponding cell-cycle proﬁles and percentages of cells undergoing increase in this anoikis revealed a Gal-3-dependent

FEBS Journal 277 (2010) 3552–3563 ª 2010 The Authors Journal compilation ª 2010 FEBS

3555

H. Sanchez-Ruderisch et al.

p16INK4a downregulates anti-anoikis effector Gal-3

A

ﬁbronectin receptor as had been shown in this and other carcinoma cell systems [9,27]. If Gal-3 interferes with Gal-1 binding to and cross-linking the a5-subunit, then Gal-3 should also negatively affect post-binding signaling by the integrin. We tested and established the involvement of caspase-8 activation for Gal-1-depen- dent anoikis induction (Fig. 6A) and revealed a nega- tive impact of Gal-3 at this level (Fig. 6B,C).

Discussion

B

0 8

0 6 1

0 6

0 2 1

0 8

0 4

s t n u o C

0 2

0 4

200

400

200

400

DNA No Gal-3

DNA + 125 µg·mL–1 Gal-3

Fig. 3. Addition of Gal-3 to the culture medium inhibits anoikis induction. (A) Gal-3 was added to p16INK4a-expressing cells (clone p16-3) in the concentrations given. Following 20 h incubation on poly-HEMA, anoikis rates were determined from DNA histograms based on the fraction of cells with subdiploid DNA content. The data are expressed as percentage of the control without the addi- tion of Gal-3 (n = 3, **P < 0.01, ***P < 0.005). (B) Representative DNA histograms in the absence (no Gal-3) or in the presence of 125 lgÆmL)1 Gal-3. The given numbers indicate the percentage of cells in the pre-G1 fraction.

The term ‘tumor suppressor’ summarizes an obvious function of a protein on malignancy. Naturally, a sup- pressor engages secondary effectors at different levels, which turn its presence as a master organizer into ren- ormalization of phenotypic characteristics. Because of growing insights into the role of glycosylation in cellu- lar communication, including growth control [6,28], we hypothesized that p16INK4a is capable of taking advan- tage of this network, explicitly by modulating the lectin reactivity of glycans and ⁄ or lectin expression. As a consequence, further study provided a novel explana- tion for why this tumor suppressor restores susceptibil- ity to anoikis in Capan-1 pancreatic carcinoma cells [9]. Having detected coordinated upregulation of both the results Gal-1 and suitable cell-surface ligands, provoked a question regarding orchestration of effects on expression in the lectin family beyond Gal-1. Evi- dently, the chimera-type Gal-3, known as a functional antagonist of Gal-1 in a tumor model, offered a prime target for study. Cumulatively,

experiments

the

to protect wild-type cells

parameter (Fig. 4D,E). Evidently, the level of Gal-3 is important from anoikis induction, and the forced expression of Gal-3 in p16INK4a-positive cells reduces their susceptibility to anoikis.

chimera-type galectin for

Because this pattern is inverse to the Gal-1-induced effects reported previously [9], it is reasonable to pro- pose functional competition between galectins-1 and -3 at the cell surface. To probe for such an effect, we stimulated anoikis by addition of Gal-1 to the culture medium. Should Gal-3 be an inhibitor, the extent of Gal-1-dependent anoikis induction via glycan binding will decrease. Stepwise increases in the Gal-3 concen- tration progressively diminished the Gal-1-dependent effect (Fig. 5A), and galectin binding, shown to be carbohydrate dependent [9], was reduced in cross-com- petition assays (Fig. 5B,C). The presence of Gal-3 can thus impair the pro-anoikis effect of Gal-1 at the level likely targeting the of

the cell surface, here most

reported herein revealed p16INK4a-dependent regulation of the presence of Gal-3 in this cell system. They also delineated a strong inﬂuence of Gal-3 on anoikis induction. Of spe- cial note, we detected functional competition at the cell surface with the recently proven pro-anoikis activity of Gal-1, which involves caspase-8 activation. Combining previous results on Gal-1 ⁄ a5b1-integrin co-immuno- precipitation, and the effects of p16INK4a on a5b1- integrin, cell-surface glycosylation and Gal-1 [3,9] with the presented data enabled us to set up a scheme of p16INK4a-orchestrated changes that favor Gal-1-depen- dent anoikis (Fig. 7). Whether and how a reduction in the intracellular activities of Gal-3 documented in other tumor cell types (e.g. interaction with oncogenic K-ras and transcriptional modulation of cell-cycle reg- ulators such as cyclins A, D1 and E as well as p21 ⁄ p27 [23,25,29]) will cooperate with the functional interfer- ence of cell-surface binding of homodimeric Gal-1, is not clear. At the cell surface, the particular proﬁle of the ligand cross-linking shown recently [30] will deﬁnitely not elicit pro-anoikis

FEBS Journal 277 (2010) 3552–3563 ª 2010 The Authors Journal compilation ª 2010 FEBS

3556

H. Sanchez-Ruderisch et al.

p16INK4a downregulates anti-anoikis effector Gal-3

A

B

C

D

E

0 2 1

0 5 1

0 2 1

0 0 1

9

10

17

22

0 0 1

0 2 1

0 8

0 9

0 6

0 4

s t n u o C

0 3

0 2

200

400

200

400

200

400

200

400

DNA Wt

DNA Mock

DNA asG3-A

DNA asG3-B

Fig. 4. Upregulation of Gal-3 in clones changes anoikis susceptibility. (A,B) Overexpression of Gal-3 protects p16INK4a-expressing clones from anoikis. (A) Increased Gal-3 content was conﬁrmed via detection of Gal-3 in western blots of clones that were stably transfected with a Gal- 3 expression construct. Blots were conducted on whole-cell lysates of Capan-1 wild-type cells (wt), a p16INK4a-expressing clone (p16) and p16INK4a-positive clones following mock transfection and with additional overexpression of Gal-3 (p16 ⁄ Mock and Gal-3 ⁄ 1-5). Blots were probed with anti-Gal-3 or anti-PCNA Ig. (B) Determination of anoikis level in ﬁve p16INK4a-positive clones with overexpression of Gal-3 and a respective mock control. Extent of anoikis is expressed as a percentage relative to the mock-transfected control clone (n = 3, *P < 0.05). (C–E) Reduction in the level of endogenous Gal-3 stimulates anoikis induction. (C) Downregulation of cellular Gal-3 was ascertained by detec- tion of Gal-3 in western blot analyses of protein extracts from wild-type (wt) and mock-transfected cells, as well as from two clones trans- fected with an antisense (as) Gal-3 cDNA construct (asG3A ⁄ B). Additional immunoblotting for PCNA (lower) was conducted to control for unspeciﬁc effects on protein synthesis. (D) Determination of level of anoikis in clones with reduced Gal-3. Summary of anoikis rates obtained in clones with decreased Gal-3 and mock controls. Anoikis rates are given as a percentage of the total number of cells (n = 3, *P < 0.05, **P < 0.01). (E) Representative cell-cycle histograms from cultures kept on poly-HEMA for 20 h. The given numbers indicate the percentage of cells in the pre-G1 fraction.

dependent communication between effector T and reg- ulatory T cells, which involves a4 ⁄ a5b1-integrins and Ca2+ inﬂux via TRPC5 channels [31]. Eventually, these investigations will unravel the mostly unexplored intricacies of the galectin network monitored in tumors by RT-PCR and by immunohistochemistry [32–34]. Such cell biological studies will then shed light on additive ⁄ synergistic, as opposed to antagonistic, activi- ties in malignancy and immune regulation.

signaling of Gal-1 in this cell system. This functional competition between galectins, described initially for SK-N-MC neuroblastoma cells and ganglioside GM1 [21], may well play a more general role in tumor growth control. Its detection gives a clear direction to further research. In this respect, such a study is warranted on the p27-dependent downregulation of carcinoma cell growth triggered by Gal-1 and most likely the a5b1-integrin [27], as well as the Gal-1 ⁄ GM1-

FEBS Journal 277 (2010) 3552–3563 ª 2010 The Authors Journal compilation ª 2010 FEBS

3557

H. Sanchez-Ruderisch et al.

p16INK4a downregulates anti-anoikis effector Gal-3

Control

FAM-LETD-FMK

A

**

*

40

200 )

**

#

%

*

30 *

##

150 ) l o r t n o c %

20 (

100 i

10 ( s l l e c c i t o t p o p A

50 s k o n A

0

24

6

16

0 Time (h)

B

C o ntrol

G al-1 + G al-3 (50 µ g· m L–1) G al-1 (100 µ g· m L–1) G al-1 + G al-3 (150 µ g· m L–1) G al-1 + G al-3 (25 µ g· m L–1) G al-1 + G al-3 (100 µ g· m L–1)

B

0 2 1

0 8

C

s t n u o C

0 4

100

101

102 Gal-3 binding (log fluorescence)

C

0 2 1

0 8

s t n u o C

0 4

100

101

102 Gal-1 binding (log fluorescence)

Fig. 6. Gal-3 affects the onset of anoikis by inhibiting Gal-1-depen- dent caspase-8 activation. (A) Anoikis after 6, 12 or 24 h incubation on poly-HEMA in the presence or absence of the caspase 8 inhibi- tor FAM-LETD-FMK. (B) Caspase 8 activation expressed as the per- centage of cells with active caspase 8 in the absence (control, ﬁlled and presence (open circles) of 100 lgÆmL)1 Gal-3 circles) (C) Anoikis (**P < 0.01, ***P < 0.001, compared with control). (percentage of cells in the pre-G1 fraction) in the absence (control, ﬁlled circles) and presence (open circles) of 100 lgÆmL)1 Gal-3 (**P < 0.01, compared with control).

expressing

galectin-7

identiﬁed

p53

reagent, without prior

Fig. 5. Gal-3 inhibits Gal-1-stimulated anoikis and Gal-1 binding. (A) Determination of Gal-1-stimulated (100 lgÆmL)1) anoikis in p16INK4a-restituted cells in the presence of increasing concentra- tions of Gal-3. Anoikis rates were determined following 20 h of culture on poly-HEMA and were calculated based on the pre-G1 fraction from cell-cycle analyses. Data are expressed as the per- centage of vehicle-treated mock control cells (n = 4, *P < 0.05, **P < 0.01, compared with control without Gal-1; #P < 0.05, ##P < 0.01 compared with data for Gal-1). (B) Binding of biotiny- lated Gal-3 in the presence (light line) or absence (bold line) of 100 lgÆmL)1 Gal-1. The dashed line signiﬁes the control with ﬂuorescent incubation with biotinylated Gal-3. (C) Binding of biotinylated Gal-1 in the presence (light line) or absence (bold line) of 150 lgÆmL)1 Gal-3. The dashed line sig- niﬁes the control.

Equally important, our study broadens the basis for galectin involvement suppressor activity. in tumor Here, the key reference point to date had been p53. In detail, SAGE screening on DLD-1 colon carcinoma cells a p53-induced gene 1 in a group of 14 genes markedly upregulated from a total of 7202 tested transcripts [35]. Along this line, genotoxic stress by UVB irradia- tion of human keratinocytes afforded a second system in which a connection between p53 and galectin-7 was

FEBS Journal 277 (2010) 3552–3563 ª 2010 The Authors Journal compilation ª 2010 FEBS

3558

H. Sanchez-Ruderisch et al.

p16INK4a downregulates anti-anoikis effector Gal-3

research,

ulation of Gal-3 expression [41–45]. The similarly consistent upregulation of Gal-1 gene expression and protein production may at ﬁrst seem puzzling. Looking at its immunohistochemical pattern, it could mostly be accounted for by a desmoplastic reaction around the tumor cells, with a Gal-1 ⁄ tissue plasminogen activator interaction being involved [44–50]. Taking our data literally, an absence or low level of Gal-1, combined with an abundance of Gal-3 in the tumor cells, seems to reﬂect impairment of p16INK4a. As shown in the Supporting Information, preliminary immunohisto- chemical analysis on a limited number of cases focus- ing on the presence of p16INK4a and Gal-3 indicated a tendency for a negative correlation, in accordance with the in vitro data. These results encourage thorough to strengthen clinical investigation of this aspect the line of relevance. By following this orchestration of galectin expression described here may become instrumental in devising a novel therapeutic strategy to rationally shift the balance between resis- tance and susceptibility to favor the anoikis process.

Materials and methods

Galectins

Fig. 7. Glycobiology of p16INK4a functionality in Capan-1 pancreatic carcinoma cells in vitro. The tumor suppressor orchestrates: an increase in the cell-surface presentation of the ﬁbronectin receptor (involving transcriptional upregulation of a5-subunit gene expres- sion), regulation of glycogenes enabling increased Gal-1 cell-surface reactivity, and an increase in the cell-surface presentation of Gal-1 (involving transcriptional upregulation of Gal-1 gene expression) [3,9]. Formation of Gal-1 ⁄ a5b1-integrin complexes with ensuing cross-linking appears to lead to anoikis induction via caspase-8 activation. Gal-3 can interfere with Gal-1 binding and ⁄ or Gal-1- dependent cross-linking at the level of the cell surface, decreasing the pro-anoikis activity of Gal-1. p16INK4a-dependent Gal-3 downre- gulation, with potential bearing also on intracellular anti-anoikis activity of Gal-3, favors the pro-anoikis effect of cell surface Gal-1.

for

Cell culture

made likely [36]. When expressed in HeLa cell transfec- tants, the intracellular function of galectin-7 appeared to relate to affecting gene expression proﬁles. Conspic- uous changes were attributed to pro-apoptosis signal- ing upstream of c-Jun N-terminal kinase activation and cytochrome c release [37]. When tested as an extracellular effector, carbohydrate-dependent binding led to growth inhibition of activated T cells or neuro- blastoma cells via caspase-dependent or -independent pathways [38,39]. Of further relevance, the recently documented effect of compensation of loss of supres- sor genes in microsatellite instability on glycosylation, including a2,6-sialylation of N-glycans, broadens the scope co-regulation [40]. Further work to strengthen this connection between a tumor suppressor and lectin ⁄ glycan remodeling as an effector pathway, especially by examining clinical samples, is clearly jus- tiﬁed.

Human galectins were produced by recombinant expression, isolated by afﬁnity chromatography on lactosylated Sepha- rose 4B as crucial step followed by gel ﬁltration, and tested for purity using 1D and 2D gel electrophoresis and nano- electrospray ionization mass spectrometry, as well as for activity by hemagglutination [9,38,51,52]. Biotinylation labeling was performed under activity-preserving conditions using the commercial N-hydroxysuccinimide ester derivative of biotin (Sigma, Munich, Germany). Its incorporation into the galectins was determined using a proteomics protocol, and the activity of the labeled proteins was checked using carbohydrate-dependent solid-phase and cell binding assays [52,53]. Polyclonal antibodies were raised in rabbits and rig- orously checked for lack of cross-reactivity using enzyme- linked immunosorbent assays and western blotting [54,55]. No experimental animals were used in this study. Monitor- ing the cell-surface presentation of galectins was carried out by ﬂow cytoﬂuorometry using ﬂuorescent goat anti-rabbit IgG with 20 lgÆmL)1 galectin-type-speciﬁc IgG fractions and FACS equipment (Becton-Dickinson, Heidelberg, Germany) [9].

Examining galectin expression in clinical samples of pancreatic cancer by gene-expression proﬁling uncov- ered a consistent, albeit quantitatively variable, upreg-

FEBS Journal 277 (2010) 3552–3563 ª 2010 The Authors Journal compilation ª 2010 FEBS

3559

Human Capan-1 pancreatic carcinoma cells and clones with stable vector-directed p16INK4a expression were established and cultured as described previously [3].

H. Sanchez-Ruderisch et al.

p16INK4a downregulates anti-anoikis effector Gal-3

Antibodies

gency of 0.1· NaCl ⁄ Cit, 0.1% SDS and exposed to X-ray ﬁlms at –70 (cid:2)C.

Nuclear run-off

Protein extraction and western blotting

Antibodies to PCNA and p16INK4a were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and NeoMarkers (Fremont, CA, USA), respectively.

Induction and detection of anoikis

(5–10 lg) were Blots were prepared using isolated and denatured cDNA fragments immobilized on Hybond N+ nylon membranes (Amersham Pharmacia). The amount of denatured cDNA for Gal-1, GAPDH and b-actin blotted was 5, 2 and 1 lgÆslot)1, respectively. Nuclear RNA preparation, labeling and hybrid- ization were performed as described previously [3]. Blots were washed twice for 10 min at 42 (cid:2)C with 40 mm NaH2PO4 ⁄ Na2HPO4 pH 7.2, 1% SDS. Labeled de novo mRNA tran- scripts were detected on autoradiographs.

Immunohistochemistry

Stable transfection of Gal-3 sense/antisense cDNA

Cells were lyzed in radioimmunoprecipitation assay buffer (50 mm Tris ⁄ HCl at pH 7.5, 0.15 m NaCl, 0.25% SDS, 0.05% sodium deoxycholate, 1% NP-40, 1 mm dithiothrei- tol, 1 lgÆmL)1 aprotinin, 2 mm leupeptin, 1 mm Na3VO4, 1 mm NaF, 1 mm phenylmethylsulfonyl ﬂuoride), and soni- subjected to cated on ice. Aliquots SDS ⁄ PAGE and electroblotted onto poly(vinylidene ﬂuo- ride) membranes (NEN, Cologne, Germany). Blots were incubated overnight at 4 (cid:2)C with the respective antibodies (diluted 1 : 1000 in 5% non-fat dried milk in phosphate Immunoreactive buffered saline with 0.5% Tween-20). bands were visualized by enhanced chemoluminescence (NEN). Cell processing, blotting and signal generation when using 2D gel electrophoresis followed the procedure previously used to detect Gal-1 [9]. For determination of anoikis, 2 · 105 cells were cultured as suspension cultures in plates coated with poly(2-hydroxy- ethyl methacrylate) (Sigma, Deisenhofen, (poly-HEMA) Germany) for the indicated times. Apoptotic cells were then quantitated from the pre-G1 fraction in cell cycle analyses as described [3].

Full-length cDNA obtained from ampliﬁcation of human Gal-3-speciﬁc mRNA of human DLD-1 colon carcinoma cells in either the sense (pcDNA–Gal-3S) or antisense subcloned into the (pcDNA–Gal-3AS) orientation was pcDNA3.1 vector, and the Effectene(cid:3) Transfection Reagent (Quiagen, Hilden, Germany) was used to generate stably transfected cells following the manufacturer’s protocol.

Determination of binding of labeled galectins

Northern blot analysis

Immunohistochemistry was performed on cryosections with antibodies controlled for speciﬁcity and lack of intergalectin cross-reactivity, as described previously [3,56,57]. Brieﬂy, sections were ﬁxed in 4% paraformaldehyde and primary antibodies were applied at a dilution of 10 lgÆmL)1 (Gal-3) or 1.25 lgÆmL)1 (p16INK4a). Immunoreactivity was detected with biotinylated secondary antibodies and avidin–biotin– peroxidase complex, with 3-amino-9-ethylcarbazole as the chromogenic substrate. Sections were counterstained with hemalaun.

Determination of caspase-8 activity

Cells were incubated with 100 lgÆmL)1 of biotinylated Gal-1 and -3, washed and surface-bound probe was detected by ﬂow cytometry using an indocarbocyanine– streptavidin conjugate. Fluorescence intensity was recorded on a FACSCalibur(cid:3) (Becton Dickinson) and analyzed with cellquest(cid:3) software [9,58]. Cells incubated with the ﬂuorescent indicator only were used to determine the back- ground ﬂuorescence.

FEBS Journal 277 (2010) 3552–3563 ª 2010 The Authors Journal compilation ª 2010 FEBS

3560

Cells with activated caspase-8 were detected using the carboxyﬂuorescein-labeled derivative of the caspase-8 in- hibitor Z-LETD-FMK (FAM-LETD-FMK) (Biocarta, Hamburg, Germany), which irreversibly binds to activated caspase-8. Fluorescence intensity was evaluated by ﬂow cytometry. Total RNA from 108 cells was isolated using RNAzol(cid:3)B (WAK-Chemie Medicals GmbH, Bad Homburg, Germany), and the poly-(A+) fraction was puriﬁed using the PolyA- Track(cid:4) System 1000 (Promega, Mannheim, Germany) according to the manufacturer’s protocol. Aliquots were separated on a 1% agarose ⁄ 3-(N-morpholino)propanesulf- onic acid ⁄ formaldehyde gel, blotted to Hybond N+ ﬁlters (Amersham Pharmacia, Freiburg, Germany) and linked to the membrane using UV light. Full-length cDNA prepara- tions for human Gal-3 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were labeled with [32P]dCTP[aP] by random priming (Megaprime DNA labeling kit; Amer- sham Pharmacia). Residual nucleotides were removed and hybridization was carried out in Quick-Hyb buffer (Strata- gene, La Jolla, CA, USA) at 65 (cid:2)C for 2 h. Following hybridization, membranes were washed at 65 (cid:2)C to a strin-

H. Sanchez-Ruderisch et al.

p16INK4a downregulates anti-anoikis effector Gal-3

Statistical analysis

Deguchi K, Detjen KM et al. (2007) Tumor suppressor p16INK4a: modulator of glycomic proﬁle and galectin-1 expression to increase susceptibility to carbohydrate- dependent induction of anoikis in pancreatic carcinoma cells. FEBS J 274, 3233–3256. Unless indicated, unpaired Student’s t-test analyses (two- tailed distribution, two-sample unequal variance) were per- formed using prism software (Prism, San Diego, CA, USA). Data were considered signiﬁcant at P-values < 0.05. 10 Reuter G & Gabius H-J (1996) Sialic acids: structure–

analysis–metabolism–occurrence–recognition. Biol Chem Hoppe Seyler 377, 325–342.

Acknowledgements

11 Patsos G & Corﬁeld A (2009) O-Glycosylation:

structural diversity and functions. In The Sugar Code. Fundamentals of Glycosciences (Gabius H-J ed), pp 111–137. Wiley-VCH, Weinheim, Germany. 12 Zuber C & Roth J (2009) N-Glycosylation. In The

Sugar Code. Fundamentals of Glycosciences (Gabius H-J ed), pp. 87–110. Wiley-VCH, Weinheim, Germany. 13 Gabius H-J (2006) Cell surface glycans: the why and

This work is dedicated to Prof. Dr Stefan Rosewicz (1960–2004), who was crucial to start this project line. We are grateful to Drs B. Friday, G. Ippans and S. Namirha for helpful comments, to L. Mantel for excel- lent technical assistance as well as to the Dr Mildred Scheel Stiftung, Sonnenfeld Stiftung, the Wilhelm-San- der-Stiftung, LMUexcellent program, the Verein zur Fo¨ rderung des biologisch-technologischen Fortschritts in der Medizin e.V. and the EC program on Marie Curie Research Training Networks (contract no. MRTN- CT-2005-019561) for generous ﬁnancial support.

how of their functionality as biochemical signals in lec- tin-mediated information transfer. Crit Rev Immunol 26, 43–79.

References

14 Villalobo A, Nogales-Gonza´ lez A & Gabius H-J (2006) A guide to signaling pathways connecting protein–gly- can interaction with the emerging versatile effector func- tionality of mammalian lectins. Trends Glycosci Glycotechnol 18, 1–37. 1 Sherr CJ (2001) The INK4a ⁄ ARF network in tumour

suppression. Nat Rev Mol Cell Biol 2, 731–737. 2 Kim WY & Sharpless NE (2006) The regulation of INK4 ⁄ ARF in cancer and aging. Cell 127, 265–275. 3 Plath T, Detjen K, Welzel M, von Marschall Z,

15 Gabius H-J, ed. (2009) The Sugar Code. Fundamentals of Glycosciences. Weinheim: Wiley-VCH, Germany. 16 Ahmad N, Gabius H-J, Kaltner H, Andre´ S, Kuwabara I, Liu F-T, Oscarson S, Norberg T & Brewer CF (2002) Thermodynamic binding studies of cell surface carbohy- drate epitopes to galectins-1, -3, and -7: evidence for differential binding speciﬁcities. Can J Chem 80, 1096– 1104. 17 Wu AM, Singh T, Wu JH, Lensch M, Andre´ S & Murphy D, Schirner M, Wiedenmann B & Rosewicz S (2000) A novel function for the tumor suppressor p16INK4a: induction of anoikis via upregulation of the a5b1 ﬁbronectin receptor. J Cell Biol 150, 1467–1478.

Gabius H-J (2006) Interaction proﬁle of galectin-5 with free saccharides and mammalian glycoproteins: probing its ﬁne speciﬁcity and the effect of naturally clustered ligand presentation. Glycobiology 16, 524–537.

4 Nakagawa H, Zheng M, Hakomori SI, Tsukamoto Y, Kawamura Y & Takahashi N (1996) Detailed oligo- saccharide structures of human integrin a5b1 analyzed by a three-dimensional mapping technique. Eur J Biochem 237, 76–85. 5 Sharon N & Lis H (1997) Glycoproteins: structure and

function. In Glycosciences: Status and Perspectives (Gabius H-J & Gabius S eds), pp 133–162. Chapman & Hall, Weinheim, Germany.

18 Andre´ S, Sansone F, Kaltner H, Casnati A, Kopitz J, Gabius H-J & Ungaro R (2008) Calix[n]arene-based glycoclusters: bioactivity of thiourea-linked galac- tose ⁄ lactose moieties as inhibitors of binding of medi- cally relevant lectins to a glycoprotein and cell-surface glycoconjugates and selectivity among human adhesion ⁄ growth-regulatory galectins. ChemBioChem 9, 1649–1661. 6 Reuter G & Gabius H-J (1999) Eukaryotic glycosyla- tion: whim of nature or multipurpose tool? Cell Mol Life Sci 55, 368–422.

7 Bellis SL (2004) Variant glycosylation: an underappreci- ated regulatory mechanism for b1 integrins. Biochim Biophys Acta 1663, 52–60.

FEBS Journal 277 (2010) 3552–3563 ª 2010 The Authors Journal compilation ª 2010 FEBS

3561

8 Honke K & Taniguchi N (2009) Animal models to delineate glycan functionality. In The Sugar Code. Fundamentals of Glycosciences (Gabius H-J ed), pp 385– 401. Wiley-VCH, Weinheim, Germany. 9 Andre´ S, Sanchez-Ruderisch H, Nakagawa H, Buchholz 19 Andre´ S, Kozˇ a´ r T, Kojima S, Unverzagt C & Gabius H-J (2009) From structural to functional glycomics: core substitutions as molecular switches for shape and lectin afﬁnity of N-glycans. Biol Chem 390, 557–565. 20 Lahm H, Andre´ S, Hoeﬂich A, Kaltner H, Siebert H-C, Sordat B, von der Lieth C-W, Wolf E & Gabius H-J (2004) Tumor galectinology: insights into the complex network of a family of endogenous lectins. Glycoconj J 20, 227–238. M, Kopitz J, Forberich P, Kemmner W, Bo¨ ck C,

H. Sanchez-Ruderisch et al.

p16INK4a downregulates anti-anoikis effector Gal-3

suppressing experimental autoimmune encephalomyeli- tis. J Immunol 182, 4036–4045.

21 Kopitz J, von Reitzenstein C, Andre´ S, Kaltner H, Uhl J, Ehemann V, Cantz M & Gabius H-J (2001) Negative regulation of neuroblastoma cell growth by carbohy- drate-dependent surface binding of galectin-1 and func- tional divergence from galectin-3. J Biol Chem 276, 35917–35923. 22 Andre´ S, Kaltner H, Lensch M, Russwurm R, Siebert 32 Lahm H, Andre´ S, Hoeﬂich A, Fischer JR, Sordat B, Kaltner H, Wolf E & Gabius H-J (2001) Comprehen- sive galectin ﬁngerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures. J Cancer Res Clin Oncol 127, 375–386.

33 Langbein S, Brade J, Badawi JK, Hatzinger M, Kaltner H, Lensch M, Specht K, Andre´ S, Brinck U, Alken P et al. (2007) Gene-expression signature of adhe- sion ⁄ growth-regulatory tissue lectins (galectins) in tran- sitional cell cancer and its prognostic relevance. Histopathology 51, 681–690. 34 Cludts S, Decaestecker C, Mahillon V, Chevalier D,

H-C, Fallsehr C, Tajkhorshid E, Heck AJR, von Knebel Doeberitz M, Gabius H-J et al. (2005) Determination of structural and functional overlap ⁄ divergence of ﬁve proto-type galectins by analysis of the growth-regulatory interaction with ganglioside GM1 in silico and in vitro on human neuroblastoma cells. Int J Cancer 114, 46–57. 23 Elad-Sfadia G, Haklai R, Balan E & Kloog Y (2004) Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phos- phoinositide 3-kinase activity. J Biol Chem 279, 34922–34930.

Kaltner H, Andre´ S, Remmelink M, Leroy X, Gabius H-J & Saussez S (2009) Galectin-8 up-regulation during hypopharyngeal and laryngeal tumor progression and comparison with galectins-1, -3 and -7. Anticancer Res 29, 4933–4940.

35 Polyak K, Xia Y, Zweier JL, Kinzler KW & Vogelstein B (1997) A model for p53-induced apoptosis. Nature 389, 300–305.

24 Yip-Schneider MT, Lin A, Barnard D, Sweeney CJ & Marshall MS (1999) Lack of elevated MAP kinase (ERK) activity in pancreatic carcinomas despite onco- genic K-Ras expression. Int J Oncol 15, 271–279. 25 Kim H-R, Lin H-M, Biliran H & Raz A (1999) Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res 59, 4148–4154.

36 Bernerd F, Sarasin A & Magnaldo T (1999) Galectin-7 overexpression is associated with the apoptotic process in UVB-induced sunburn keratinocytes. Proc Natl Acad Sci USA 96, 11329–11334. 26 Schaffert C, Pour PM & Chaney WG (1998) Localiza- tion of galectin-3 in normal and diseased pancreatic tissue. Int J Pancreatol 23, 1–9. 27 Fischer C, Sanchez-Ruderisch H, Welzel M, Wieden-

37 Kuwabara I, Kuwabara Y, Yang RY, Schuler M, Green DR, Zuraw BL, Hsu DK & Liu F-T (2002) Galectin-7 (PIG1) exhibits pro-apoptotic function through JNK activation and mitochondrial cytochrome c release. J Biol Chem 277, 3487–3497.

mann B, Sakai T, Andre´ S, Gabius H-J, Khachigian L, Detjen KM & Rosewicz S (2005) Galectin-1 interacts with the a5b1 ﬁbronectin receptor to restrict carcinoma cell growth via induction of p21 and p27. J Biol Chem 280, 37266–37277.

38 Kopitz J, Andre´ S, von Reitzenstein C, Versluis K, Kaltner H, Pieters RJ, Wasano K, Kuwabara I, Liu F-T, Cantz M et al. (2003) Homodimeric galectin-7 (p53-induced gene 1) is a negative growth regulator for human neuroblastoma cells. Oncogene 22, 6277–6288. 39 Sturm A, Lensch M, Andre´ S, Kaltner H, Wiedenmann 28 Andre´ S, Kopitz J, Kaltner H, Villalobo A & Gabius H-J (2009) Glycans as functional markers in malig- nancy? In The Sugar Code. Fundamentals of Glyco- sciences (Gabius H-J ed), pp 419–432. Wiley-VCH, Weinheim, Germany.

B, Rosewicz S, Dignass AU & Gabius H-J (2004) Human galectin-2: novel inducer of T cell apoptosis with distinct proﬁle of caspase activation. J Immunol 173, 3825–3837. 40 Patsos G, Andre´ S, Roeckel N, Gromes R, Gebert J,

29 Smetana K Jr, Dvorˇ a´ nkova´ B, Chovanec M, Boucˇ ek J, Klı´ ma J, Motlı´ k J, Lensch M, Kaltner H, Andre´ S & Gabius H-J (2006) Nuclear presence of adhesion ⁄ growth-regulatory galectins in normal ⁄ malignant cells of squamous epithelial origin. Histochem Cell Biol 125, 171–182.

30 Ahmad N, Gabius H-J, Andre´ S, Kaltner H, Sabesan S, Roy R, Liu B, Macaluso F & Brewer CF (2004) Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes. J Biol Chem 279, 10841– 10847. 31 Wang J, Lu ZH, Gabius H-J, Rohowsky-Kochan C, Kopitz J & Gabius H-J (2009) Compensation of loss of protein function in microsatellite-unstable colon cancer cells (HCT116): a gene-dependent effect on the cell surface glycan proﬁle. Glycobiology 19, 726–734. 41 Terris B, Blaveri E, Crnogorac-Jurcevic T, Jones M, Missiaglia E, Ruszniewski P, Sauvanet A & Lemoine NR (2002) Characterization of gene expression proﬁles in intraductal papillary-mucinous tumors of the pan- creas. Am J Pathol 160, 1745–1754. 42 Gru¨ tzmann R, Pilarsky C, Ammerpohl O, Lu¨ ttges J,

FEBS Journal 277 (2010) 3552–3563 ª 2010 The Authors Journal compilation ª 2010 FEBS

3562

Ledeen RW & Wu G (2009) Cross-linking of GM1 gan- glioside by galectin-1 mediates regulatory T cell activity involving TRPC5 channel activation: possible role in Bo¨ hme A, Sipos B, Foerder M, Alldinger I, Jahnke B, Schackert HK et al. (2004) Gene expression proﬁling of

H. Sanchez-Ruderisch et al.

p16INK4a downregulates anti-anoikis effector Gal-3

microdissected pancreatic ductal carcinomas using high- density DNA microarrays. Neoplasia 6, 611–622. endogenous lectins: their reactivities in solid-phase and cell assays and conformational analysis by molecular dynamics simulations. Bioorg Med Chem 14, 6314–6326. 53 Purkrabkova´ T, Smetana K Jr, Dvora´ nkova´ B,

43 Lu Z, Hu L, Evers S, Chen J & Shen Y (2004) Differen- tial expression proﬁling of human pancreatic adenocar- cinoma and healthy pancreatic tissue. Proteomics 4, 3975–3988.

44 Pogue-Geile KL, Mackey JA, George RD, Wood PG, Lee KKW, Moser AJ, Tillman DL, Lyons-Weiler J & Whitcomb DC (2004) A new microarray, enriched in pancreas and pancreatic cancer cDNAs to identify genes relevant to pancreatic cancer. Cancer Genomics Proteo- mics 1, 371–386.

Holikova´ Z, Bo¨ ck C, Lensch M, Andre´ S, Pytlı´ k R, Liu F-T, Klı´ ma J et al. (2003) New aspects of galectin functionality in nuclei of cultured bone marrow stromal and epidermal cells: biotinylated galectins as tool to detect speciﬁc binding sites. Biol Cell 95, 535–545. 54 Kaltner H, Seyrek K, Heck A, Sinowatz F & Gabius H-J (2002) Galectin-1 and galectin-3 in fetal develop- ment of bovine respiratory and digestive tracts. Comparison of cell type-speciﬁc expression proﬁles and subcellular localization. Cell Tissue Res 307, 35–46.

45 Ide Y, Miyoshi E, Nakagawa T, Gu J, Tanemura M, Nishida T, Ito T, Yamamoto H, Kozutsumi Y & Taniguchi N (2006) Aberrant expression of N-acetylglu- cosaminyltransferase-IVa and IVb (GnT-IVa and b) in pancreatic cancer. Biochem Biophys Res Commun 341, 478–482.

55 Lohr M, Kaltner H, Lensch M, Andre´ S, Sinowatz F & Gabius H-J (2008) Cell-type-speciﬁc expression of murine multifunctional galectin-3 and its association with follicular atresia ⁄ luteolysis in contrast to pro- apoptotic galectins-1 and -7. Histochem Cell Biol 130, 567–581.

46 Berberat PO, Friess H, Wang L, Zhu Z, Bley T, Frigeri L, Zimmermann A & Buchler MW (2001) Comparative analysis of galectins in primary tumors and tumor metastasis in human pancreatic cancer. J Histochem Cytochem 49, 539–549.

56 Cˇ ada Z, Smetana K Jr, Lacina L, Plza´ kova´ Z, Sˇ tork J, Kaltner H, Russwurm R, Lensch M, Andre´ S & Gabius H-J (2009) Immunohistochemical ﬁngerprinting of the network of seven adhesion ⁄ growth-regulatory lectins in human skin and detection of distinct tumour-associated alterations. Folia Biol (Praha) 55, 145–152. 57 Szabo P, Dam TK, Smetana K Jr, Dvora´ nkova´ B,

47 Iacobuzio-Donahue CA, Ashfaq R, Maitra A, Adsay NV, Shen-Ong GL, Berg K, Hollingsworth MA, Cameron JL, Yeo CJ, Kern SE et al. (2003) Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription proﬁles obtained from three major technologies. Cancer Res 63, 8614–8622. 48 Shen J, Person MD, Zhu J, Abbruzzese JL & Li D

Ku¨ bler D, Brewer CF & Gabius H-J (2009) Phosphory- lated human lectin galectin-3: analysis of ligand binding by histochemical monitoring of normal ⁄ malignant squa- mous epithelia and by isothermal titration calorimetry. Anat Histol Embryol 38, 68–75.

(2004) Protein expression proﬁles in pancreatic adeno- carcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimen- sional gel electrophoresis and mass spectrometry. Cancer Res 64, 9018–9026.

58 Andre´ S, Maljaars CEP, Halkes KM, Gabius H-J & Kamerling JP (2007) Discovery of galectin ligands in fully randomized combinatorial one-bead-one-com- pound (glyco)peptide libraries. Bioorg Med Chem Lett 17, 793–798.

Supporting information

The following supplementary material is available: Fig. S1. Evidence for negative correlation between Gal-3 and p16INK4a in human pancreatic tissue and pancreatic cancer.

This supplementary material can be found in the

49 Chen R, Yi EC, Donohoe S, Pan S, Eng J, Cooke K, Crispin DA, Lane Z, Goodlett DR, Bronner MP et al. (2005) Pancreatic cancer proteome: the proteins that underlie invasion, metastasis, and immunologic escape. Gastroenterology 129, 1187–1197. 50 Roda O, Ortiz-Zapater E, Martı´ nez-Bosch N,

online version of this article.

Gutie´ rrez-Gallego R, Vila-Perello´ M, Ampurdane´ s C, Gabius H-J, Andre´ S, Andreu D, Real FX et al. (2009) Galectin-1 is a novel functional receptor for tissue plasminogen activator in pancreatic cancer. Gastroenterology 136, 1379–1390.

Please note: As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer-reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing ﬁles) should be addressed to the authors.

51 Gabius H-J, Engelhardt R, Rehm S & Cramer F (1984) Biochemical characterization of endogenous carbohy- drate-binding proteins from spontaneous murine rhab- domyosarcoma, mammary adenocarcinoma, and ovarian teratoma. J Natl Cancer Inst 73, 1349–1357. 52 Andre´ S, Pei Z, Siebert H-C, Ramstro¨ m O & Gabius

FEBS Journal 277 (2010) 3552–3563 ª 2010 The Authors Journal compilation ª 2010 FEBS

3563

H-J (2006) Glycosyldisulﬁdes from dynamic combinato- rial libraries as O-glycoside mimetics for plant and